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Abstract
Ras small GTPases are activated in many hematopoietic growth factor signaling and in
hematological malignancies, but their role in hematopoiesis and leukemogenesis is not completely
known. Here we examined the effect of Ras inhibition by a dominant negative mutant of Ras, N17
H-Ras, in adult hematopoiesis and in BCR/ABL leukemogenesis using the mouse bone marrow
transduction and transplantation approach. We found that N17 H-Ras expression suppressed B-
and T-lymphopoiesis and erythropoiesis. Interestingly, N17 H-Ras did not suppress myelopoiesis
in the bone marrow, yet it greatly attenuated BCR/ABL-induced chronic myelogenous leukemia
(CML)-like myeloproliferative disease. Most BCR/ABL + N17 H-Ras mice eventually developed
pro-B lymphoblastic leukemia/lymphoma (B-ALL). These results suggest that Ras activation is
essential for the development of lymphoid and erythroid cells but not myeloid cells and that Ras is
a critical target of BCR/ABL in the pathogenesis of CML, but not B-ALL.
Background
Ras proteins are small GTPases that act as molecular
switches, transducing signals from activated receptors to
downstream effectors to regulate cell proliferation, sur-
vival and differentiation [1]. Members of the Ras family
include three cellular Ras genes, which encode four highly
homologous proteins: H-, N-, and K-Ras4A and 4B, the
latter two being alternatively spliced isoforms differing
only at the carboxyl terminus (with alternative 4th exon)
[2]. H-, N-, and K-Ras proteins are widely expressed, with
K-Ras expressing in almost all cell types [3]. The four Ras
proteins share an identical amino-terminal region. This
region includes the nucleotide binding and effector loop
domains, providing a basis for the ability of Ras proteins
to interact with a common set of activators and effectors
and to share many biochemical and biological functions.
The next 80 amino acids are also highly homologous
(85% identity) among all four Ras proteins. Conversely,
the Ras proteins diverge highly at the carboxyl-terminal
23–24 amino acids, referred to as the hypervariable
domain (HVR) [4]. This HVR domain signals the post-
translational modifications that enable the Ras proteins to
attach to the inner surface of the plasma membrane, a pre-
requisite for Ras-mediated signal transduction. Different
modifications and targeting mechanisms result in locali-
zation of the Ras proteins to functionally distinct micro-
domains of the plasma membrane, which may allow the
Ras proteins access to different pools of Ras regulators
and/or effectors and, therefore, generate distinct signal
outputs [3].
Gene knockout studies in mice have revealed functional
differences as well as redundancies between Ras proteins.
Mice that lack the expression of N-Ras or H-Ras or both
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[5,6]. But the mice lacking the K-Ras gene die during
embryonic development between days 12 (E12) and 14
(E14), with fetal liver defects and evidence of anemia
[7,8]. These results demonstrate that K-Ras provides a
unique and essential function during mouse develop-
ment. Interestingly, the mice heterozygous for K-Ras (K-
Ras+/-) and homozygous null for N-Ras (N-Ras-/-) die
between E10 and 12, while the K-Ras+/- mice are normal.
Furthermore, no viable double homozygous mutant (K-
Ras-/-; N-Ras-/-) was recovered at E9.5. These results suggest
that there is partial redundancy between Ras proteins [7].
In addition to their normal cellular functions, Ras pro-
teins play critical roles in tumorigenesis. Mutated Ras
genes are associated with approximately 30% of all
human cancers, including both solid tumors and hemato-
logical malignancies [9]. In addition to the direct activa-
tion by mutations, Ras can also be functionally activated
by other oncogenic mutations, such as the BCR/ABL
fusion protein.
BCR/ABL is produced when the breakpoint cluster region
gene (BCR) sequences on chromosome 22 are fused to
ABL sequences on chromosome 9 by a reciprocal translo-
cation [10]. The BCR/ABL fusion protein is present in
nearly all patients with chronic myelogenous leukemia
(CML) and in 20% of the adult and 2–5% of the pediatric
patients with B-acute lymphoblastic leukemia (B-ALL).
We and others have shown that expression of BCR/ABL in
mouse bone marrow cells by retroviral transduction effi-
ciently induces a myeloproliferative disease (MPD)
resembling human CML [11,12]. In this model system,
BCR-ABL with a mutation (Y177F) at the tyrosine-177 res-
idue – a high affinity-binding site for the Grb2 SH2
domain when phosphorylated [13,14] – induced a T cell
leukemia and lymphoma after a prolonged latent period
[15-17]. Grb2 is an SH2- and SH3-containing adapter pro-
tein that binds Sos – a guanine nucleotide exchange factor
(GEF) of Ras – as well as the scaffolding adapter Gab2
[18]. These interactions activate Ras, and recruits phos-
photidylinositol-3 kinase (PI3-K) and the protein tyrosine
phosphatase SHP2 [13,14,18]. The importance of Y177 in
the induction of CML-like MPD by BCR-ABL suggests that
activation of Ras signaling pathways plays a critical role in
the pathogenesis of CML. Consistent with this result,
BCR/ABL transformation was shown to be blocked by
interfering with Ras function using either a dominant neg-
ative mutant of Ras or the catalytic domain of Ras-GAP
[19].
The redundant function among Ras proteins makes it dif-
ficult to assess the importance of Ras in development and
tumorigenesis. The Ras mutant that contains an asparag-
ine at position 17 functions as a competitive inhibitor of
the normal endogenous wild-type Ras for the binding of
GEFs [1]. The N17 H-Ras mutant has been shown to be
the most effective in inhibiting the activation of all three
isoforms of Ras in the cell, due to the wide distribution of
this protein throughout the plasma membrane as com-
pared to K-Ras and N-Ras [20-22]. To assess the role of Ras
in adult hematopoiesis and in BCR/ABL leukemogenesis,
and to assess the importance of Ras as a therapeutic target,
we examined the effect of N17 H-Ras mutant in bone mar-
row reconstitution and in the induction of CML-like MPD
by BCR/ABL in mice.
Methods
DNA constructs
A vector capable of expressing N17 H-Ras and BCR/ABL
fused to GFP on the 3' end of BCR/ABL in identical levels
was made through a multistep cloning strategy. The
MSCV-BCR/ABL-GFP-IRES-N17Ras was constructed as
follows: The dominant negative Ras (N17 H-Ras) (gener-
ous gift provided by Dr. Hong Cai in Dana-Farber Cancer
Institute) was amplified by PCR using the primers 5'CGC
GGA TCC ATG ACA GAA TAC AAG CTT GTG GTC3' and
5'ACG CGT CGA CTC AGG AGA GCA CAC ACT TGC AGC
T3' which contain a Bam HI and Sal I internal sites. The
PCR product was digested with Bam HI and Sal I, cloned
into pBluescript II/SK- (Stratagene, La Jolla, CA) into the
Bam HI/Sal I sites, and then sequenced to verify that there
were no introduced mutations. This N17 H-Ras sequence
was then compared with the H-Ras sequence of the Gen-
bank database (Accession #J00277). To clone the N17 H-
Ras fragment into the pCITE (Novagen, Madison, WI) vec-
tor that carries the IRES (internal ribosomal entry site)
sequence necessary to allow the Ras expression, the N17
H-Ras fragment was ligated to the annealed adapters 5'
CAT GGC GGC CGC TG 3' and 3' CGC CGG CGA CCT AG
5' to generate a Nco I site which was necessary for cloning
into pCITE. This construct was then cut with Eco RI and
Sal I to isolate the Ras insert to clone it into MSCV retro-
viral vector [23]. This vector is capable of transducing
genes with high efficiency into undifferentiated murine
embryonic carcinomas and hematopoietic stem cells. GFP
or BCR/ABL-GFP fusion protein was cloned into the EcoRI
site of MSCV as described previously [24]. In order to
clone the IRES-neo fragment a similar strategy as
described above was followed to clone the other construct
MSCV-BCR/ABL-GFP-IRES-Neo. Another vector capable
of expressing N17 H-Ras and GFP on the 5': MSCV-GFP-
IRES-N17 H-Ras was constructed as follows: The GFP was
amplified by PCR using the primers 5' AAG AAT TCG
CGG CCG CCA TGA CAG AAT ACA AGC TTG TGG TGG
TG3' AND 5'AAG AAT TCG CGG CCG CTC AGG AGA
GCA CAC ATT GCA GCT CAT G3' which contain an Eco
RI and Not I internal sites. The PCR product was digested
with Eco RI, cloned into MSCV-IRES-N17 H-Ras into the
Eco RI site. Orientation was checked by enzyme digestion.Page 2 of 13
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structed as described before [12].
Cell culture, retrovirus preparation and viral titer 
quantification
NIH 3T3 and BOSC 23 cells were grown as previously
described [25,26]. Helper-free retroviruses were generated
by transient transfection of retroviral DNA constructs into
BOSC 23 cells as previously described [12,25]. Retroviral
transduction and tittering was performed as described
[12,25]. All viruses were adjusted to equal titer based on
GFP expression just before transduction of BM cells or
other cell types.
Transformation assays of cell lines in vitro
NIH 3T3 cells (1 × 105) were plated on 60 mm Petri dish.
After 18 hours the cells were infected for 4 hs with 1 ml,
0.5 ml, 0.1 ml, 0.01 ml, or 0.001 ml of retroviral superna-
tant per duplicate plates. Seven to ten days after infections
the plates corresponding to the different retroviral dilu-
tions were analyzed and the number of Foci quantified.
For bone marrow soft agar colony assays, the retroviral-
transduced cells were washed twice in excess phosphate-
buffered saline (PBS) (GIBCO BRL, Grand Island, N.Y.),
counted and plated into six-well plates at 105 cells per well
(0.3% Bacto agar, 20% FBS, 200 U of penicillin/ml, 200
μg of streptomycin/ml, 50 M 2-mercaptoethanol in
DMEM).
Infection, transplantation and colony assay of bone 
marrow cells
Bone marrow cell infection and transplantation were per-
formed as described previously [12]. Briefly, 5-fluoroucil
(5-FU)- treated bone marrow cells (1 × 106 cells/ml) from
male Balb/c (Taconic Farm, Germantown, NY) donor
mice (5 to 6 weeks old) were infected for 24 hours in a
cocktail containing DMEM, 15% FCS, 5% WEHI-condi-
tioned medium, 7 ng/ml IL-3 (Genzyme, Cambridge,
MA), 12 ng/ml IL-6 (R&D System, Minneapolis, MN), 56
ng/ml stem cell factor (SCF, R&D System), 2 mM L-
glutamine (GIBCO BRL), 100 μg/ml streptomycin, 100 U/
ml penicillin, 0.25 μg/ml amphotericin B (GIBCO BRL), 2
μg/ml polybrene and 30% of retroviral supernatant. After
24 hours, the bone marrow cells were re-infected with
freshly made retroviruses. Two days post infection, the
bone marrow cells were washed once with PBS and then
injected into lethally irradiated (2 doses of 450 rads given
4 hours apart) syngeneic female BALB/c mice (5 to 6
weeks old) through tail vein injection of 4 × 105 cells per
mouse. The secondary bone marrow transplant was per-
formed with 5 × 106 whole bone marrow cells from mice
reconstituted with MSCV-IRES-GFP or MSCV-GFP-IRES-
N17 Ras bone marrow cells into lethaly irradiated BALB/c
mice.
In vitro soft agar colony assays were performed as
described previously [26] with modifications. From the
infected cells used for bone marrow transplantation, 105
infected BM cells were plated in 35-mm-diameter cells in
DMEM, 20% FCS, 100 μg of streptomycin/ml, 100 U of
penicillin/ml, 0.25 μg of amphoterecin B/ml, 50 μM 2-
mercaptoethanol (Sigma), and 0.3% bacto-agar, on top of
a layer of medium containing 0.6% bacto-agar. Colonies
were counted on day 15. BM liquid cultures were grown
in the absence of cytokines. Cytospin preparations of
these cultures were stained with Hema-3.
In vitro methylcellulose colony assays
Bone marrow cells for in vitro methylcellulose colony
assays were either isolated from bone marrow of our ret-
roviral transduced mice or were obtained from double ret-
roviral infection of 5-FU enriched isolated bone marrow
cells from 5–6 weeks male Balb/c mice (Taconic Farm,
Germantown, NY) [12]. Upon isolation, these cells were
immediately sorted for GFP positive populations as
described previously [12,25].
MethoCult™ CF M3434 and MethoCult™ M3334 (Stem-
Cell Technologies, Vancouver, BC, Canada) were used for
myeloid and erythroid colony assays respectively. Sorted
GFP positive cells were diluted to 2.0 × 105 cells/mL in Isc-
cove's MDM (IMDM, StemCell Technologies, Inc.) with
2% FBS for MethoCult™ CF M3434 and 2 × 106 cells/mL
for MethoCult™ M3334. 0.3 mL of cells were added to
aliquoted 3 mL of MethoCult™ CF M3434 and MethoC-
ult™ M3334 for duplicate cultures. Tubes of the MethoC-
ult™ CF M3434 and MethoCult™ M3334 containing the
cells were vortexed and bubbles were allowed to rise and
dissipate for 5–10 minutes. 1.1 mL of the culture was dis-
pensed into each of two 35 mm culture dishes using a 3 cc
syringe and 16 g blunt end needle. Cultures in MethoC-
ult™ CF M3434 were incubated for 10 days and cultures in
MethoCult™ M3334 for 5 days at 37°C and 5% CO2a
humidified incubator.
Analysis of disease phenotype in mice
Hematopathological analysis was performed as previ-
ously described [12,25]. Total blood cells and white blood
cells (WBCs) were counted on Coulter Counter (Model
Z1; Coulter Particle Characterization, Hialeah, Fla.).
Immunophenotypes of hematopoietic cells and leukemic
cells were determined by flow cytometry. Flow cytometry
and cell sorting were performed as described [12].
Western blot analysis
Total cell lysates of BM cells or NIH 3T3 cells were pre-
pared as described [25]. Proteins were separated on a 6–
15% gradient SDS-polyacrilamide gel electrophoresis
(SDS-PAGE) and electrophoretically transferred to nitro-
cellulose filters (Schleicher & Schuell, Keene, NH). The fil-Page 3 of 13
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3 (Oncogene Research Products, Cambridge, MA), rat
anti-Ras monoclonal antibody (Santa Cruz Biotechnol-
ogy, Inc. Santa Cruz, CA), anti-dynamin (Transduction
Laboratories, Lexington, KY), anti-actin (clone AC-40,
Sigma, St. Louis, MO, USA), anti-phospho-p44/42
(Thr202/Tyr204) MAP kinases (Erk1 and Erk2), anti-p44/
42 MAP kinases (Erk1 and Erk2) (New England Biolabs,
Beverly, MA, USA). Bound antibodies were visualized by
using horseradish peroxidase-conjugated anti-mouse, anti
rabbit, or anti-rat IgG respectively (Southern Biotechnol-
ogy Associates, Inc., Birmingham, AL, USA).
Mice perfusion
Mice were anesthetized and then cut from the lower abdo-
men to the chest to expose heart, lungs, liver and thymus.
A 18-gauge needle was inserted through the left ventricle
of the heart into the ascending aorta, and slowly perfused
the animal with 50 ml room temperature PBS until the
blood was replaced by the saline fluid and liver was
blanched to a yellow color. The right atrium of the heart
was cut to suction the outflow.
Results
Expression of N17 H-Ras inhibits hematopoiesis
Prior to examine the role of Ras activation in BCR/ABL
leukemogenesis using N17 H-Ras, we examined the effect
of N17 H-Ras in hematopoiesis. To facilitate identifica-
tion of N17 H-Ras expressing cells and determination of
virus titers, we cloned into MSCV the gene encoding GFP
linked together with the N17 H-Ras mutant gene by an
internal ribosome entry site (IRES), which allows both
GFP and N17 H-Ras to be translated from the same tran-
script. The MSCV-IRES-GFP retroviral vector was used as a
control. The expression of N17 H-Ras was confirmed in
infected NIH 3T3 cells (data not shown).
To introduce N17 H-Ras into hematopoietic stem/progen-
itor cells, we infected the 5-FU-treated primary bone mar-
row cells with N17 H-Ras or GFP control retroviruses and
then transplanted the infected cells to recipient mice (see
Material and Methods). Four weeks after bone marrow
transplantation (BMT), GFP-positive cells were seen in the
bone marrow, spleen, and peripheral white blood cells of
mice that received the control vector (Figure 1 and data
not shown). GFP-positive cells were greatly reduced in
mice that were transplanted with bone marrow cells
infected with the N17 H-Ras construct (Figure 1). Similar
results were seen in the bone marrow of N17 H-Ras mice
8 and 12 weeks post-BMT (data not shown). These results
indicate that suppression of Ras activation by N17 H-Ras
inhibits bone marrow reconstitution/hematopoiesis. The
effect of N17 H-Ras in the development of specific blood
lineages was analyzed as follows.
Ras activation is critical for B-lymphopoiesis
B220+ cells with various levels of GFP expression (both
high and low) were seen in GFP control mice (Figure 1).
The number of GFP-positive B220+ cells was much lower
in mice that were transplanted with bone marrow cells
infected with the N17 H-Ras construct than that in GFP
control mice (Figure 1). In particular, GFPhigh B220+ cells
were not detected in N17 H-Ras mice. Retrovirus-medi-
ated transgene expression varies in target cells depending
on its site of integration in the host chromosome. It has
been shown that there is a tight correlation of the expres-
sion level of the transgene placed downstream of the IRES
and the expression of the transgene cloned between the
retroviral LTR and the IRES [27]. The absence of B220+
cells expressing high levels of GFP in N17 H-Ras mice sug-
gests that high expression of N17 H-Ras, thus more effec-
tive inhibition of Ras, suppresses B-lymphopoiesis. In
other words, certain level of Ras activation is essential for
B-lymphopoiesis. We further examined the phenotype of
the remaining B220+ cells (GFPlow).
In mouse bone marrow, all B lineage cells express in their
surface the B220 (CD45R) marker. In addition, B lym-
phoid cells can be identified as seven distinct categories
corresponding to specific stages of differentiation by ana-
lyzing the expression of CD43, HSA (CD24), BP-1, IgM
and IgD [28]. We found that GFP and B220 gated bone
marrow cells from the N17 Ras transduced mice were
CD43+, HSA+, BP-1- and IgM- (Figure 2 and data not
shown). These results indicate that B cell development can
be blocked at the pro-B cell stage even with low levels of
N17 H-Ras expression. In other words, the development
of B-lymphocytes from pro-B to pre-B cell stage requires
high levels of Ras activation.
Ras activation is required for erythropoiesis
Like B lymphoid cells, the number of GFP-positive
Ter119+ (erythroid) cells was also significantly reduced in
N17 H-Ras mice compared to that in GFP control mice
(Figure 1). GFPhigh erythroid cells were absent in N17 H-
Ras mice, too. These results suggest that Ras activation is
required for erythropoiesis.
To evaluate response of the remaining GFPlow erythroid
cells to erythropoietin (Epo), we isolated GFP positive
bone marrow cells from N17 H-Ras mice and control mice
by FACS sorting and then plated the same number of cells
on methylcellulose in the presence of Epo. The total
number of erythroid colonies was significantly decreased
under Ras inhibition (Figure 3A). The decrease is largely
attributed to BFU-Es, since the ratio of CFU-E to BFU-E
was much higher for the N17 H-Ras than the GFP control
(Figure 3B). This result indicates that full Ras activation is
required for efficient growth of BFU-E in response to Epo.Page 4 of 13
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To assess the role of Ras in thymocyte development, we
examined whole thymuses of N17 H-Ras and GFP control
mice for the presence of GFP positive cells. To prevent
contamination of GFP positive cells present in the circula-
tion of these mice, we perfused the mice with PBS before
isolating the thymuses from the control and N17 H-Ras
mice. Flow cytometric analyses of the control mice show
the presence of GFP positive T cells in both the thymus
and periphery (Figure 4 and data not shown). However,
the absence of GFP positive cells in the periphery of the
N17 Ras mice, together with the very low percentage
(~0.4%) of GFP positive cells in the thymuses of these
mice (Figure 4 and data not shown) indicates that inhibi-
tion of Ras activation blocks thymocyte development. The
presence of some GFP positive cells in the thymus suggests
that the block is not at the level of migration of lymphoid
progenitor cells from bone marrow to thymus.
Ras activation is not required for myeloid cell development 
in the bone marrow
Even though constitutive activation and mutations in the
Ras genes have been directly implicated in many forms of
malignancies of myeloid hematological origin [9], Ras
role in normal myeloid lineage development was not
known. To better understand Ras function in myelopoie-
sis we analyzed the presence of myeloid cells by staining
Mac-1 and Gr-1 markers in N17 H-Ras and GFP control.
Surprisingly, a relatively large population of GFP+ Mac-1/
Gr-1 positive cells was seen in the bone marrow (Figure
1). In particular, unlike B lymphoid and erythroid cells,
there are both GFPhigh and GFPlow myeloid cell popula-
Flow cytometric analysis of spleen and bone marrow cells from N17 H-Ras and GFP control miceigure 1
Flow cytometric analysis of spleen and bone marrow cells from N17 H-Ras and GFP control mice. Expression of 
GFP (X-axis) and Mac-1, B220, Terr-119, or Gr-1 (Y-axis) in bone marrow cells and splenocytes isolated from N17 H-Ras and 
GFP control mice was analyzed by flow cytometry. Results are representative of one of the three independent experiments.Page 5 of 13
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expressed in bone marrow cells (data not shown).
To further evaluate the role of Ras activation in myeloid
cell proliferation and differentiation, we examined the
effect of N17 H-Ras in bone marrow cell growth in vitro.
Bone marrow cells from N17 H-Ras mice and control
mice were sorted for GFP positive populations and then
the same number of cells were plated and cultured on
methylcellulose in the presence of cytokines that support
myeloid cell growth. We found that the total number of
myeloid colonies formed from bone marrow cells of N17
H-Ras mice and of control mice were similar (Figure 5).
Moreover, differentiation of myeloid cells was not
affected by Ras inhibition as seen by the growth and dif-
ferentiation of those cells into different types of CFU-GM
colonies (Type I, II, III, and IV) (Figure 5). Together, these
results suggest that Ras activation seems to be dispensable
in the development of myeloid cells in the bone marrow.
The lower total number of GFP positive myeloid cells seen
in N17 H-Ras mice (Figure 1) may be due to the reduction
of more primitive progenitor cells.
Ras activation is required for the induction of CML-like 
MPD by BCR/ABL
Having shown that myelopoiesis is not suppressed by
expression of N17 H-Ras, we moved to examine the effect
of N17 H-Ras in BCR/ABL leukemogenesis. We generated
MSCV-BCR/ABL-GFP-IRES-N17H-Ras and MSCV-BCR/
ABL-GFP-IRES-Neo retroviral constructs (Figure 6A). Fus-
ing GFP to BCR/ABL facilitates viral tittering and identifi-
cation of infected cells. We have shown previously that
BCR/ABL-GFP still induces CML-like MPD efficiently
[12]. A neomycin gene (Neo) was cloned downstream of
IRES as a control. To characterize these constructs, we
infected NIH 3T3 cells with MSCV-BCR/ABL-GFP-IRES-
N17H-Ras, MSCV-BCR/ABL-GFP-IRES-Neo, and MSCV-
IRES-GFP retroviruses, respectively. Figure 6B shows that
infection of NIH 3T3 cells with titer-matched MSCV-BCR/
ABL-GFP-IRES-N17H-Ras and MSCV-BCR/ABL-GFP-
IRES-Neo retroviruses yielded similar levels of BCR/ABL-
GFP expression, as shown by western blotting using an
anti-Abl antibody. The expression of N17 H-Ras appears
as a bigger protein compared to the endogenous Ras (lane
3). This difference in size is due to the presence of an
adapter introduced to the N-terminus of the protein (see
Materials and Methods). Consistent with the inhibition of
Ras activation by N17 H-Ras, phosphorylation of Erk1
and 2 proteins was reduced in NIH 3T3 cells expressing
BCR/ABL-GFP and N17H-Ras compared to that in NIH
3T3 cells expressing BCR/ABL-GFP and Neo (Figure 6B).
To characterize the transforming potential of MSCV-BCR/
ABL-GFP-IRES-N17H-Ras and MSCV-BCR/ABL-GFP-
IRES-Neo constructs, we performed in vitro transforma-
tion assays using NIH 3T3 fibroblasts and primary BM
Immunophenotyping of GFPlow B-lymphoid cells from bone marrow of N17 H-Ras miceFigure 2
Immunophenotyping of GFPlow B-lymphoid cells from bone marrow of N17 H-Ras mice. Flow cytometry analysis 
of gated GFP-positive B220+ bone marrow cells isolated from N17 H-Ras mice. Cells were stained with CD43, HAS and BP-1 
as indicated.Page 6 of 13
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Ras inhibition affects erythroid proliferation and differentiation in vitroFigure 3
Ras inhibition affects erythroid proliferation and differentiation in vitro. A). Total colony counts of sorted GFP bone 
marrow cells from N17 Ras and control GFP mice. The same number of cells was plated in methylcellulose media in the pres-
ence of Epo. Colonies were counted 2 and 5 days after plating for BFU-Es and CFU-Es respectively. Results revealed that the 
growth of bone marrow cells is affected by Ras inhibition. B) The number of BFU-E and CFU-E colonies derived from GFP 
sorted cells from N17 Ras and control GFP mice were quantified as the percentage of total number of erythroid colonies 
present for each group at day 5. Results are shown as the mean ± standard deviation of two independent experiments.
Journal of Hematology & Oncology 2008, 1:5 http://www.jhoonline.org/content/1/1/5cells. As shown previously [19], expression of N17 H-Ras
greatly inhibited BCR/ABL transformation in all these
cells (Table 1).
To examine the effect of N17 H-Ras in BCR/ABL leukemo-
genesis in vivo, we transplanted the MSCV-BCR/ABL-GFP-
IRES-N17H-Ras, MSCV-BCR/ABL-GFP-IRES-Neo, or
MSCV-IRES-GFP-infected 5-FU treated bone marrow cells
into lethally irradiated syngeneic recipient mice. As
expected, BCR/ABL-GFP rapidly induced a fatal CML-like
MPD (Figure 7 and data not shown). The BCR/ABL-GFP +
N17Ras mice also developed a fatal disease, but with a
much longer latent period compared to BCR/ABL-GFP
mice (Figure 7). No sign of disease was found in GFP con-
trol mice in the same period of time (data not shown).
As shown previously, BCR/ABL-GFP induced murine
CML-like MPD is characterized by high white blood cell
(WBC) counts with granulocyte predominance, hepat-
osplenomegaly and pulmonary hemorrhages owing to
extensive granulocyte infiltration and extramedullary
hematopoiesis (data not shown). In contrast, myelopro-
liferation was moderate in BCR/ABL-GFP + N17 H-Ras
mice (data not shown). More importantly the myelopro-
liferation disorder was transient. The vast majority of
BCR/ABL-GFP + N17 H-Ras mice contain increasing
amount of pro-B cells and eventually succumbed to B
lymphoblastic leukemia and/or lymphoma (Table 2 and
data not shown). These results suggest that Ras activation
plays a critical role in BCR/ABL-induced MPD but not
lymphoid malignancy.
Discussion
Expression of the N17 H-Ras transgene under the control
of the Eμ enhancer and the lck proximal promoter arrests
B cell development at the pro-B cell stage [29]. Our exper-
iment did not show GFPhigh B lymphoid cells, suggesting
that high-levels of N17 H-Ras expression completely sup-
pressed B-lymphopoiesis. There are two critical differ-
ences between our experiment and the previous one. One
difference is the cells into which the N17 H-Ras was tar-
geted. In previous experiment, the Eμ enhancer first
becomes active in the pre-pro-B cells, whereas in our
experiment, MSCV may drive the transgene expression in
more primitive progenitor cells and completely block dif-
ferentiation of such cells into B cell lineage. The other
essential difference involves the expression levels of N17
H-Ras. Retrovirus-mediated transgene expression varies in
target cells depending on its site of integration in the host
chromosome. When a strong retroviral LTR promoter/
enhancer is combined with certain integration sites, the
transgene can be highly expressed in target cells. This may
result in more effective suppression of Ras activation. Our
finding that low expression of N17 H-Ras blocked B-lym-
phocyte development at the pro-B cell stage is consonant
with, and builds upon, what was found previously. Taken
together, these results offer two insights. First, certain lev-
els of Ras activation are required for the earliest B-lym-
Ras activation is essential for thymocyte developmentFigure 4
Ras activation is essential for thymocyte development. Thymocytes from control and N17 Ras mice were analyzed by 
flow cytometry after whole mouse perfusion for the detection of GFP cells.Page 8 of 13
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Ras inhibition does not affect myeloid proliferation and differentiation in vitroFigure 5
Ras inhibition does not affect myeloid proliferation and differentiation in vitro. A). Total colony counts of sorted 
GFP bone marrow cells from N17 Ras and control GFP mice. The same number of cells was plated in methylcellulose media in 
the presence of IL-3, IL-6 and SCF. Colonies were counted 10 days after plating. B) Colonies derived from GFP sorted cells 
from N17 Ras and control GFP mice were morphologically characterized 10 days after plating. Four different kinds of CFU-GM 
colonies: Type a (I), b (II), c (III), and d (IV) were identified for both N17 Ras and GFP control mice. C) Colonies were quanti-
fied as the percentage of each of the types present for both groups. Results are shown as the mean ± standard deviation of 
three independent experiments.
Journal of Hematology & Oncology 2008, 1:5 http://www.jhoonline.org/content/1/1/5phocyte development. Second, the development of B-
lymphocytes from pro-B to pre-B cell stage requires high
levels of Ras activation.
Expression of the N17 H-Ras transgene under the control
of the lck proximal promoter has been shown to nearly
completely block the proliferation of thymocytes in
response to T cell receptor (TCR) stimulation and severely
impair the positive selection of thymocytes [30]. In this
report we found that the development of thymocytes was
completely blocked by N17 H-Ras expression, at both
high and low expression levels. As discussed above, the
difference may due to targeting N17 H-Ras expression
into different cells. Lck is first expressed in double nega-
tive (DN) thymocytes, whereas MSCV may target N17 H-
Ras expression into earlier T lymphocyte precursors and/
Structure of retroviral vectors used to transduce GFP, BCR/ABL-GFP and BCR/ABL-GFP + N17 H-Ras and their expression in NIH 3T3 cellsFigure 6
Structure of retroviral vectors used to transduce GFP, BCR/ABL-GFP and BCR/ABL-GFP + N17 H-Ras and 
their expression in NIH 3T3 cells. (A) LTR: long terminal repeat. Enzyme abbreviations: Cl, Cla I; RI, EcoRI; N, Not I; S, Sal 
I. (B) NIH 3T3 cells were infected with titer-matched MSCV-IRES-GFP (lane 1), MSCV-BCR/ABL-GFP-IRES-Neo (lane 2), and 
MSCV- BCR/ABL-GFP-IRES-N17 H-Ras (lane 3) retroviruses. The corresponding cell lysates were subjected to SDS-PAGE and 
analyzed by Western blot, probed with anti-Abl monoclonal antibody AB-3, anti-Ras monoclonal antibody and anti-dynamin (as 
a loading control).
Table 1: Transforming potential of BCR-ABL-GFP vs. BCR-ABL-GFP + N17 H-Ras
Cells Assays BCR-ABL-GFP* BCR-ABL-GFP + N17 H-Ras* GFP vector*
NIH 3T3 # of foci 117 +/- 16† 11 +/- 2 -
Bone marrow # of colonies 16 +/- 0.6 0.33 +/- 0.33 -
* Retroviral titers were matched.
†Results are shown as the mean ± SD of three independent experiments.Page 10 of 13
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vation is critical for early thymocyte development.
Similar to the effect of N17 H-Ras in B-lymphocyte devel-
opment, high expression of N17 H-Ras completely sup-
pressed erythopoiesis, whereas low expression of N17 H-
Ras inhibited the expansion of BFU-E, but not CFU-E. A
recent study also showed that dominant negative Ras does
not reduce CFU-E colony formation [31].
In contrast to the critical role of Ras activation in lym-
phopoiesis and erythropoiesis, myelopoiesis seemed not
to be blocked by expression of N17 H-Ras. It is possible
that there are redundant pathways downstream of mye-
loid growth receptors that regulate proliferation and sur-
vival of myeloid cells. It has been shown that both
oncogenic Ras and STAT5 can induce myeloproliferative
disease [32-34], yet adult hematopoiesis appears normal
in STAT5A/B-deficient mice [35]. These two pathways
may overlap in promoting myeloid cell proliferation and
survival.
As mentioned in the introduction, BCR-ABL with a muta-
tion at the tyrosine-177 residue – a high affinity-binding
site for the Grb2 SH2 domain [13,14] – induced a T cell
leukemia and lymphoma after a prolonged latent period
[15-17]. Consistent with the idea that Ras is a critical
downstream target of Y177, N17 H-Ras greatly attenuates
BCR/ABL's ability to induce the fatal CML-like MPD.
However, unlike the BCR/ABL Y177F phenotype, BCR/
ABL-GFP + N17 H-Ras mice developed B, instead of T,
lymphoblast leukemia/lymphoma. These results suggest
that the Y177 motif in BCR/ABL also regulates signaling
pathway(s) other than Ras. Indeed, in addition to recruit-
ing the Ras activator Sos, Grb2 also binds the scaffolding
adapter Gab2, which in turn recruits SHP2 and PI3K [18].
It has been shown that the ability of BCR/ABL to confer
cytokine-independent growth of primary myeloid cells
isolated from Gab2-/- mice in vitro was significantly
reduced [18]. These results suggest the latter signaling
pathways also play important roles mediating Y177 func-
tion in BCR/ABL.
Inhibiting Ras activation by N17 H-Ras has its limitations,
as using dominant negative mutants in general. For exam-
ple, Ras GEFs may have other substrates. Inhibiting Ras
GEF, therefore, may affect molecules other than Ras. How-
ever, our findings show that the effect of N17 H-Ras in
hematopoiesis is lineage, developmental stage, and dos-
age dependent. This differential role of Ras in the reconsti-
Cumulative survival of BCR/ABL-GFP and BCR/ABL-GFP + N17 H-Ras miceFigure 7
Cumulative survival of BCR/ABL-GFP and BCR/ABL-GFP + N17 H-Ras mice. Survival curve of BCR/ABL-GFP and 
BCR/ABL-GFP + N17 H-Ras mice was generated by Kaplan-Meier survival analysis. N: number of recipient mice.
Table 2: Summary of diseases developed in BCR-ABL-GFP and BCR-ABL-GFP + N17 H-Ras mice
Mice CML B-lymphoid leukemia/lymphoma ND*
BCR-ABL-GFP 7/7 0/7 -
BCR-ABL-GFP+ N17 H-Ras 2/12 8/12 2/12
* Not determined.Page 11 of 13
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leukemogenesis warrants further studies.
Conclusion
In this study we assessed the importance of Ras in BCR/
ABL leukemogenesis and the potential toxicity of inhibit-
ing Ras in normal hematopoiesis and found that inhibi-
tion of Ras activation by N17 H-Ras suppresses the
development of erythrocytes, T and B-lymphocytes, but
not myeloid cells. In addition, the presence of N17 H-Ras
greatly attenuated BCR/ABL-induced chronic myeloge-
nous leukemia (CML)-like myeloproliferative disease.
Most BCR/ABL + N17 H-Ras mice eventually developed B
lymphoblastic leukemia/lymphoma. These results suggest
that Ras activation is important for the development of
lymphoid and erythroid cells but not myeloid cells, and
that Ras is a critical target of BCR/ABL in the pathogenesis
of CML, but not B-ALL.
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